Introduction: Avoiding potentially fatal complications, such as radiogenic second cancer, are of particular importance for pediatric patients due to a relatively longer survival time after their treatment and higher degree of radiation sensitivity compared to adults. Medulloblastoma, one of the most common pediatric brain tumors, has the standard of care of a combination of craniospinal irradiation (CSI) and chemo therapy after surgery. There are some comparative studies of treatment plan and risks of second cancer for pediatric patients received CSI. However, those previous studies either did not calculate the risk of second cancer (1), or did not include stray neutron dose in proton therapy (2) or underestimated stray photon dose in photon therapy (3). The objective of this study was to compare contemporary photon and proton radiation therapies in terms of the risks of second cancers for a pediatric patient receiving CSI. To the best knowledge of the authors', this is the first time that both therapeutic and stray radiation doses were included in dosimetric and risk comparison between photon and proton CSI. Calculation methods: Both proton and photon treatment plans were created using a commercial treatment planning system (Eclipse version 8.9, Varian Medical Systems). The stray neutron dose in proton therapy was obtained by Monte Carlo simulation using MCNPX code, the stray photon dose in photon therapy was obtained by TLD measurement. The dose-risk model based on Biological Effects of Ionization Radiation VII (4) report was used to estimate risk of second cancer. The advanced dose reconstruction tools in our group provided us with the most accurate comprehensive evaluation of radiation doses and risks from CSI. Figure 1 (a) and (b) show proton and photon therapeutic absorbed dose distribution for this patient. However, the dose fall-off in the photon plan is much more gradual resulting in higher doses in regions anterior to the vertebral bodies. Figure 1 (c) shows the stray neutron dose distribution to a pediatric patient from proton CSI. Although the stray neutron dose is much lower in magnitude compared to the therapeutic proton dose, it penetrates the whole body of the patient and is not negligible.
Gy (RBE)

lists mean organ equivalent doses from proton and photon radiation treatment plans for this patient. For each organ and for the remainder, the equivalent dose was at least a factor of 4 higher for photon therapy than for proton therapy.
Table 1
Mean organ equivalent doses from proton and photon CSI plans for a 4-year-old boy. For proton CSI, both therapeutic and stray doses were listed, and a summation of them was also listed. (Due to the methodology used to calculate photon dose, it was not possible to separate therapeutic dose from stray dose in photon CSI). For photon CSI, the combined dose from both therapeutic and stray doses was listed. 
